GC said it has launched Pojinen cream, a compound treatment for recurrent herpes labialis.Herpes labialis is a disease caused by infection with the herpes virus, which remains in the body for life. The virus is usually dormant but becomes active when the immune system weakens, causing blisters, itch
Gemvax & KAEL said that it had received approval from the Ministry of Food and Drug Safety for a phase 3 clinical trial to evaluate the efficacy and safety of GV1001 in patients with moderate to severe Alzheimer's disease.The company plans to conduct a multicenter, randomized, double-blind, placebo-
Discontinuation or exposure of Pfizer’s Ibrance (ingredient: palbociclib), the first CDK4/6 inhibitor, was not related to the drug’s failure to show additional benefit in combination with endocrine therapy in treating early breast cancer, a study showed.The study excluded the exposure of Ibrance fro
Sanofi said its interleukin-4/13 inhibitor Dupixent (dupilumab) aimed to treat chronic pruritus with high clinically unmet demand.On Tuesday, the Ministry of Food and Drug Safety allowed Sanofi to conduct a phase 3 trial of Dupixent.Sanofi plans to conduct two randomized, double-blind, placebo-contr
inno.N disclosed a plan to develop a selective RET inhibitor targeted therapy, which the company acquired from Voronoi, a Korean new drug R&D company.On Wednesday, inno.N introduced four anticancer drug pipelines at the JP Morgan Healthcare Conference.The company said it completed a non-clinical tri
Celltrion said that Swissmedic, Switzerland’s drug administration, has temporary authorization for Regkirona (ingredient: regdanvimab).Celltrion submitted the results of large-scale global phase 3 clinical trials and preclinical data on various variants, including the Delta, to the Swissmedic, which
Handok said that it began the exclusive sales of Mircera, Roche's chronic kidney disease anemia treatment, on Jan. 1.Mircera (ingredient name: methoxypolyethylene glycol-epoetin beta) is a third-generation erythrocyte hematopoietic stimulator to treat symptomatic anemia in patients with chronic kidn
Novartis’ breakthrough cancer treatment Kymriah (ingredient: tisagenlecleucel), which costs over 500 million won ($421,000), has become eligible for reimbursement, the health insurance review agency said. The agency also recognized the need for an expanded reimbursement for Keytruda (pembrolizumab)
Shaperon received the regulatory nod to conduct a local phase 2b/3 trial of NuSepin, a Covid-19 treatment candidate.Upon the approval of the Ministry of Food and Drug Safety (MFDS), Shaperon will evaluate NuSepin intravenous infusion’s dosage, efficacy, and safety in 1,134 patients hospitalized for
SK Plasma said Thursday that it would shed its image as a company specializing only in blood products to expand and reorganize its business portfolio into rare, incurable diseases.The company will officially kick off an investment project for rare, incurable diseases with Tium Bio and Korea Investme
AstraZeneca said the U.S. government agreed to purchase additional 500,000 doses of its Covid-19 preventive medicine Evusheld (tixagevimab/cilgavimab).AZ had said that it would initially supply 1 million doses of Evusheld. However, if most of the doses go to the U.S., other countries will have limit
TGF-β R1 inhibitor Vactosertib, an anticancer therapy being developed by MedPacto, caused unexpected serious adverse reactions of skin toxicity and hepatotoxicity when combined with immunotherapy in a recent trial.MedPacto submitted a plan to the Ministry of Food and Drug Safety to reduce the dose a
Jeil Pharmaceutical said it has received marketing approval from the Ministry of Food and Drug Safety for Triferic (ingredient: sodium ferric citrate iron sulfate precipitation hydrate), an iron supplement.The company received approval for Triferic as an iron supplement therapy for maintaining hemog
SK Bioscience said Wednesday that it has obtained the product license for Nuvaxovid, Novavax's Covid-19 vaccine, from the Ministry of Food and Drug Safety.Nuvaxovid is the first Covid-19 vaccine in Korea to receive approval as a synthetic antigen-based vaccine. The company applied for permission on
Liveome, a subsidiary of Medytox, has signed contract development and manufacturing organization (CDMO) contracts with Australia’s Luina Bio and U.K.’s Quay Pharma to develop an inflammatory bowel disease candidate, LIV001.Luina Bio will provide raw materials, and Quay Pharma will make finished prod
ABL Bio said that it has signed a joint development and technology transfer contract with Sanofi for ABL301, a dual antibody candidate for treating degenerative brain diseases like Parkinson's disease.Under the accord, ABL Bio will receive a down payment of $75 million. It can also receive up to $98
Daewoong Pharmaceutical is busy preparing for a market launch of Fexuclue Tab. (fexuprazan hydrochloride), a treatment for gastroesophageal reflux disease (GERD).Daewoong plans the rollout of Fexuclue in the first half of this year to make it compete against inno.N’s K-Cab (tegoprazan).Daewoong is r
Hanmi Pharm will manufacture a DNA-based Covid-19 vaccine approved by a national regulator for the first time in the world.The company said it signed a contract manufacturing organization (CMO) agreement with Enzychem Lifesciences on the technology transfer and production facility preparation to man
The regulator authorized MSD’s anti-PD-1 immunotherapy Keytruda (pembrolizumab) in combination with Eisai’s oral multiple receptor tyrosine kinase inhibitor Lenvima (lenvatinib) as the first-line treatment of renal cell carcinoma (RCC).It also confirmed the combination therapy’s indication for endom
Hyundai Pharm’s operating profit and net profit turned to a deficit last year, drawing the industry’s attention to its background.On Monday, the company released changes in its profit and loss structure in a public notice. The announcement was due to the changes of more than 30 percent in its profit